File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: DAS181 inhibits H5N1 influenza virus infection of human lung tissues
  • Basic View
  • Metadata View
  • XML View
TitleDAS181 inhibits H5N1 influenza virus infection of human lung tissues
 
AuthorsChan, RWY1
Chan, MCW1
Wong, ACN1
Karamanska, R3
Dell, A3
Haslam, SM3
Sihoe, ADL1
Chui, WH1
TrianaBaltzer, G2
Li, Q2
Malik Peiris, JS1
Fang, F2
Nicholls, JM1
 
Issue Date2009
 
PublisherAmerican Society for Microbiology.
 
CitationAntimicrobial Agents And Chemotherapy, 2009, v. 53 n. 9, p. 3935-3941 [How to Cite?]
DOI: http://dx.doi.org/10.1128/AAC.00389-09
 
AbstractDAS181 is a novel candidate therapeutic agent against influenza virus which functions via the mechanism of removing the virus receptor, sialic acid (Sia), from the adjacent glycan structures. DAS181 and its analogues have previously been shown to be potently active against multiple strains of seasonal and avian influenza virus strains in several experimental models, including cell lines, mice, and ferrets. Here we demonstrate that DAS181 treatment leads to desialylation of both α2-6-linked and α2-3-linked Sia in ex vivo human lung tissue culture and primary pneumocytes. DAS181 treatment also effectively protects human lung tissue and pneumocytes against the highly pathogenic avian influenza virus H5N1 (A/Vietnam/3046/2004). Two doses of DAS181 treatment given 12 h apart were sufficient to block H5N1 infection in the ex vivo lung tissue culture. These findings support the potential value of DAS181 as a broad-spectrum therapeutic agent against influenza viruses, especially H5N1. Copyright © 2009, American Society for Microbiology.
 
ISSN0066-4804
2012 Impact Factor: 4.565
2012 SCImago Journal Rankings: 1.963
 
DOIhttp://dx.doi.org/10.1128/AAC.00389-09
 
PubMed Central IDPMC2737896
 
ISI Accession Number IDWOS:000270014200043
Funding AgencyGrant Number
NIHHHSN266200600015C
1U01AI070281
Hong Kong GovernmentRFCID08070842
University Grants Committee of the Hong Kong Special Administrative Region, ChinaAoE/M-12/06
NIH NIAIDHHSN266200600015C
Wellcome Trust082098
BBSRC
CERG773507M
Funding Information:

This study was supported in part by NIH contracts HHSN266200600015C and 1U01AI070281, grant RFCID08070842 from the Hong Kong Government, and CERG773507M and the Area of Excellence program on influenza supported by the University Grants Committee of the Hong Kong Special Administrative Region, China ( project AoE/M-12/06). The work at NexBio was supported in part by NIH NIAID contract HHSN266200600015C. S. M. H. and A. D. acknowledge the support of the Wellcome Trust ( grant 082098) and the BBSRC.

 
ReferencesReferences in Scopus
 
GrantsControl of Pandemic and Inter-pandemic Influenza
 
DC FieldValue
dc.contributor.authorChan, RWY
 
dc.contributor.authorChan, MCW
 
dc.contributor.authorWong, ACN
 
dc.contributor.authorKaramanska, R
 
dc.contributor.authorDell, A
 
dc.contributor.authorHaslam, SM
 
dc.contributor.authorSihoe, ADL
 
dc.contributor.authorChui, WH
 
dc.contributor.authorTrianaBaltzer, G
 
dc.contributor.authorLi, Q
 
dc.contributor.authorMalik Peiris, JS
 
dc.contributor.authorFang, F
 
dc.contributor.authorNicholls, JM
 
dc.date.accessioned2010-09-06T07:49:35Z
 
dc.date.available2010-09-06T07:49:35Z
 
dc.date.issued2009
 
dc.description.abstractDAS181 is a novel candidate therapeutic agent against influenza virus which functions via the mechanism of removing the virus receptor, sialic acid (Sia), from the adjacent glycan structures. DAS181 and its analogues have previously been shown to be potently active against multiple strains of seasonal and avian influenza virus strains in several experimental models, including cell lines, mice, and ferrets. Here we demonstrate that DAS181 treatment leads to desialylation of both α2-6-linked and α2-3-linked Sia in ex vivo human lung tissue culture and primary pneumocytes. DAS181 treatment also effectively protects human lung tissue and pneumocytes against the highly pathogenic avian influenza virus H5N1 (A/Vietnam/3046/2004). Two doses of DAS181 treatment given 12 h apart were sufficient to block H5N1 infection in the ex vivo lung tissue culture. These findings support the potential value of DAS181 as a broad-spectrum therapeutic agent against influenza viruses, especially H5N1. Copyright © 2009, American Society for Microbiology.
 
dc.description.naturelink_to_OA_fulltext
 
dc.identifier.citationAntimicrobial Agents And Chemotherapy, 2009, v. 53 n. 9, p. 3935-3941 [How to Cite?]
DOI: http://dx.doi.org/10.1128/AAC.00389-09
 
dc.identifier.doihttp://dx.doi.org/10.1128/AAC.00389-09
 
dc.identifier.eissn1098-6596
 
dc.identifier.epage3941
 
dc.identifier.hkuros160048
 
dc.identifier.isiWOS:000270014200043
Funding AgencyGrant Number
NIHHHSN266200600015C
1U01AI070281
Hong Kong GovernmentRFCID08070842
University Grants Committee of the Hong Kong Special Administrative Region, ChinaAoE/M-12/06
NIH NIAIDHHSN266200600015C
Wellcome Trust082098
BBSRC
CERG773507M
Funding Information:

This study was supported in part by NIH contracts HHSN266200600015C and 1U01AI070281, grant RFCID08070842 from the Hong Kong Government, and CERG773507M and the Area of Excellence program on influenza supported by the University Grants Committee of the Hong Kong Special Administrative Region, China ( project AoE/M-12/06). The work at NexBio was supported in part by NIH NIAID contract HHSN266200600015C. S. M. H. and A. D. acknowledge the support of the Wellcome Trust ( grant 082098) and the BBSRC.

 
dc.identifier.issn0066-4804
2012 Impact Factor: 4.565
2012 SCImago Journal Rankings: 1.963
 
dc.identifier.issue9
 
dc.identifier.openurl
 
dc.identifier.pmcidPMC2737896
 
dc.identifier.pmid19596886
 
dc.identifier.scopuseid_2-s2.0-70349122523
 
dc.identifier.spage3935
 
dc.identifier.urihttp://hdl.handle.net/10722/79018
 
dc.identifier.volume53
 
dc.languageeng
 
dc.publisherAmerican Society for Microbiology.
 
dc.publisher.placeUnited States
 
dc.relation.ispartofAntimicrobial Agents and Chemotherapy
 
dc.relation.projectControl of Pandemic and Inter-pandemic Influenza
 
dc.relation.referencesReferences in Scopus
 
dc.rightsAntimicrobial Agents and Chemotherapy. Copyright © American Society for Microbiology.
 
dc.rightsCopyright © American Society for Microbiology, [insert journal name, volume number, page numbers, and year]
 
dc.subject.meshAntiviral Agents - pharmacology
 
dc.subject.meshInfluenza A Virus, H5N1 Subtype - drug effects
 
dc.subject.meshInfluenza, Human - prevention and control - virology
 
dc.subject.meshLung - cytology - drug effects - virology
 
dc.subject.meshRecombinant Fusion Proteins - pharmacology
 
dc.titleDAS181 inhibits H5N1 influenza virus infection of human lung tissues
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Chan, RWY</contributor.author>
<contributor.author>Chan, MCW</contributor.author>
<contributor.author>Wong, ACN</contributor.author>
<contributor.author>Karamanska, R</contributor.author>
<contributor.author>Dell, A</contributor.author>
<contributor.author>Haslam, SM</contributor.author>
<contributor.author>Sihoe, ADL</contributor.author>
<contributor.author>Chui, WH</contributor.author>
<contributor.author>TrianaBaltzer, G</contributor.author>
<contributor.author>Li, Q</contributor.author>
<contributor.author>Malik Peiris, JS</contributor.author>
<contributor.author>Fang, F</contributor.author>
<contributor.author>Nicholls, JM</contributor.author>
<date.accessioned>2010-09-06T07:49:35Z</date.accessioned>
<date.available>2010-09-06T07:49:35Z</date.available>
<date.issued>2009</date.issued>
<identifier.citation>Antimicrobial Agents And Chemotherapy, 2009, v. 53 n. 9, p. 3935-3941</identifier.citation>
<identifier.issn>0066-4804</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/79018</identifier.uri>
<description.abstract>DAS181 is a novel candidate therapeutic agent against influenza virus which functions via the mechanism of removing the virus receptor, sialic acid (Sia), from the adjacent glycan structures. DAS181 and its analogues have previously been shown to be potently active against multiple strains of seasonal and avian influenza virus strains in several experimental models, including cell lines, mice, and ferrets. Here we demonstrate that DAS181 treatment leads to desialylation of both &#945;2-6-linked and &#945;2-3-linked Sia in ex vivo human lung tissue culture and primary pneumocytes. DAS181 treatment also effectively protects human lung tissue and pneumocytes against the highly pathogenic avian influenza virus H5N1 (A/Vietnam/3046/2004). Two doses of DAS181 treatment given 12 h apart were sufficient to block H5N1 infection in the ex vivo lung tissue culture. These findings support the potential value of DAS181 as a broad-spectrum therapeutic agent against influenza viruses, especially H5N1. Copyright &#169; 2009, American Society for Microbiology.</description.abstract>
<language>eng</language>
<publisher>American Society for Microbiology.</publisher>
<relation.ispartof>Antimicrobial Agents and Chemotherapy</relation.ispartof>
<rights>Antimicrobial Agents and Chemotherapy. Copyright &#169; American Society for Microbiology.</rights>
<rights>Copyright &#169; American Society for Microbiology, [insert journal name, volume number, page numbers, and year]</rights>
<subject.mesh>Antiviral Agents - pharmacology</subject.mesh>
<subject.mesh>Influenza A Virus, H5N1 Subtype - drug effects</subject.mesh>
<subject.mesh>Influenza, Human - prevention and control - virology</subject.mesh>
<subject.mesh>Lung - cytology - drug effects - virology</subject.mesh>
<subject.mesh>Recombinant Fusion Proteins - pharmacology</subject.mesh>
<title>DAS181 inhibits H5N1 influenza virus infection of human lung tissues</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0066-4804&amp;volume=53&amp;issue=9&amp;spage=3935&amp;epage=3941&amp;date=2009&amp;atitle=DAS181+inhibits+H5N1+influenza+virus+infection+of+human+lung+tissues</identifier.openurl>
<description.nature>link_to_OA_fulltext</description.nature>
<identifier.doi>10.1128/AAC.00389-09</identifier.doi>
<identifier.pmid>19596886</identifier.pmid>
<identifier.pmcid>PMC2737896</identifier.pmcid>
<identifier.scopus>eid_2-s2.0-70349122523</identifier.scopus>
<identifier.hkuros>160048</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-70349122523&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>53</identifier.volume>
<identifier.issue>9</identifier.issue>
<identifier.spage>3935</identifier.spage>
<identifier.epage>3941</identifier.epage>
<identifier.eissn>1098-6596</identifier.eissn>
<identifier.isi>WOS:000270014200043</identifier.isi>
<publisher.place>United States</publisher.place>
<relation.project>Control of Pandemic and Inter-pandemic Influenza</relation.project>
<bitstream.url>http://hub.hku.hk/bitstream/10722/79018/1/re01.htm</bitstream.url>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. NexBio, Inc.
  3. Imperial College London